文献
J-GLOBAL ID:202102276057797267
整理番号:21A0023570
移植前MRD陰性度は,再発性/難治性急性リンパ芽球性白血病に対する,CAR-T療法の良好な転帰を予測する: 多施設後向き研究【JST・京大機械翻訳】
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
著者 (59件):
Zhao Houli
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Zhao Houli
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Zhao Houli
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Wei Jieping
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Wei Jieping
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Wei Jieping
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Wei Guoqing
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Wei Guoqing
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Wei Guoqing
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Luo Yi
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Luo Yi
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Luo Yi
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Shi Jimin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Shi Jimin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Shi Jimin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Cui Qu
(Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China)
,
Zhao Mingfeng
(Department of Hematology, Tianjin First Central Hospital, Tianjin, China)
,
Liang Aibin
(Department of Hematology, Shanghai Tongji Hospital, Shanghai, China)
,
Zhang Qing
(Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China)
,
Yang Jianmin
(Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China)
,
Li Xin
(Department of Hematology, Xiangya Third Hospital, Changsha, China)
,
Chen Jing
(Department of Hematology, Shanghai Children’s Medical Center, Shanghai, China)
,
Song Xianmin
(Department of Hematology, Shanghai General Hospital, Shanghai, China)
,
Jing Hongmei
(Department of Hematology, Peking University Third Hospital, Beijing, China)
,
Li Yuhua
(Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China)
,
Hao Siguo
(Department of Hematology, Xinhua Hospital of Shanghai, Shanghai, China)
,
Wu Wenjun
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Wu Wenjun
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Wu Wenjun
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Tan Yamin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Tan Yamin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Tan Yamin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Yu Jian
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Yu Jian
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Yu Jian
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Zhao Yanmin
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Zhao Yanmin
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Zhao Yanmin
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Lai Xiaoyu
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Lai Xiaoyu
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Lai Xiaoyu
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Yin Elaine Tan Su
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Yin Elaine Tan Su
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Yin Elaine Tan Su
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Wei Yunxiong
(Department of Hematology, Tianjin First Central Hospital, Tianjin, China)
,
Li Ping
(Department of Hematology, Shanghai Tongji Hospital, Shanghai, China)
,
Huang Jing
(Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China)
,
Wang Tao
(Department of Hematology, Changhai Hospital of Shanghai, Shanghai, China)
,
Blaise Didier
(Institut Paoli-Calmettes, Marseille, France)
,
Xiao Lei
(Innovative Cellular Therapeutics Co, Ltd, Shanghai, China)
,
Chang Alex H.
(Shanghai YaKe Biotechnology Ltd, Shanghai, China)
,
Nagler Arnon
(Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel)
,
Mohty Mohamad
(Sorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Paris, France)
,
Huang He
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Huang He
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Huang He
(Institute of Hematology, Zhejiang University, Hangzhou, China)
,
Hu Yongxian
(Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China)
,
Hu Yongxian
(Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China)
,
Hu Yongxian
(Institute of Hematology, Zhejiang University, Hangzhou, China)
資料名:
Journal of Hematology & Oncology (Web)
(Journal of Hematology & Oncology (Web))
巻:
13
号:
1
ページ:
1-13
発行年:
2020年
JST資料番号:
U7517A
ISSN:
1756-8722
資料種別:
逐次刊行物 (A)
記事区分:
短報
発行国:
イギリス (GBR)
言語:
英語 (EN)